Last week, our co-founder Jan Nelis attended the Sachs Associates 24th Annual Biotech in Europe Forum in Basel. We had the opportunity to present an update on Ariya Bio's progress and plans and engage with investors, partners, and peers. If you want to learn more about how we turn blood stem cells into living drug factories, reach out to us. #genetherapy #biotech #CRISPR #startup
Ariya Bio
Biotechnologieforschung
Schlieren, Zürich 659 Follower:innen
We turn red blood cells into protein factories
Info
At Ariya Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.
- Website
-
ariyabio.ch
Externer Link zu Ariya Bio
- Branche
- Biotechnologieforschung
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Schlieren, Zürich
- Art
- Privatunternehmen
Orte
-
Primär
Wagistrasse 18
Schlieren, Zürich 8952, CH
Beschäftigte von Ariya Bio
-
Jan Nelis
Co-Founder and Project Lead at Ariya Bio
-
Amir Taheri-Ghahfarokhi
Research Lead at Ariya Bio, Genome Editor
-
Thea Bill Andersen
Molecular biologist | Creativity and analytical thinking to create a better tomorrow | Dr. sc. ETH Zurich #humanhealth #sustainability…
-
Federico Costanzo
Scientist | R&D | Molecular Biology | Functional Genomics | Drug Discovery
Updates
-
Exciting News: 💥 Ariya Bio has been accepted into the renowned Innosuisse Core Coaching program. After successfully completing the initial coaching program during the past year, we are now advancing to the next stage. This gives us access to valuable resources and experienced coaches to further refine our strategy. We want to especially thank Michael Wacker, our lead coach, for his invaluable and continued advice. We look forward to many engaging and enriching discussions. (https://lnkd.in/dVXu2dk) #genetherapy #biotech #CRISPR #startup
-
The newly published FDA draft guidance on the Platform Technology Designation Programs is a big leap for the Cell and Gene Therapy industry. Also, for Ariya Bio , this draft guidance is greatly informative and promising. It outlines a path on how to accelerate the development of curative treatments based on our novel CRISPR-Cas based gene therapy platform. #genetherapy #CRISPRCAS #platform #CGT
Today, FDA issued a draft guidance that outlines how a well-understood and reproducible technology in an FDA-approved drug or biological product may be eligible for a platform technology designation: https://lnkd.in/egqRQuiv
-
Last week, our founder Jan Nelis had the fantastic opportunity to exchange and engage with innovators and facilitators in the cell and gene therapy space at the Advanced Therapies Congress in London. We presented an update on our best-in-class lead programs in sickle cell disease and β-thalassemia and discussed our platform's potential to develop cures for multiple inherited disorders. Learn more about how we combine two powerful technologies, hematopoietic stem cell therapy and CRISPR Cas gene editing, to develop transformative genomic medicines at www.ariyabio.ch
-
We're thrilled to welcome Amir Taheri-Ghahfarokhi to the team at Ariya Bio as our new Research Lead and co-founder! With his past experiences in both large and small biotech companies, Amir brings extensive expertise in CRISPR Cas gene editing and DNA repair pathways, which will be invaluable as we work to bring curative treatments to patients in need. Join us in congratulating Amir and learn more about our mission to cure hemoglobinopathies at https://www.ariyabio.ch/
-
It was truly amazing to engage with RNA therapeutics enthusiasts and innovators at yesterday's Swiss RNA Therapeutics Summit in Bern. Our Co-Founder, Jan Nelis, shared some insights into the exciting work we do at Ariya Bio. Stay tuned for future updates on our Hemoglobinopathy programs and beyond. We want to thank NCCR RNA & Disease for this amazing opportunity and the continued support provided to researchers and entrepreneurs. #geneediting #biotech #crispr #genetherapy #redbloodcells #ariyabio
-
Join us at the CRISPR Medicine News Conference in April, where our Co-Founder Jan Nelis will be giving an update on Ariya Bio`s progress.
I am thrilled to announce that I'll be speaking at the CRISPR Medicine News Conference in April about Ariya Bio`s work on developing cures for some of the most common inherited disorders worldwide. Excited to share our progress!
-
Recently our work was featured in CRISPR Medicine News. Thank you, Karen O'Hanlon Cohrt, PhD, for this fantastic article which gives an overview of our journey so far and future plans. Help us bring a cure to diseases that really need one! #geneediting #biotech #crispr #genetherapy #ariyabio
𝐒𝐭𝐚𝐫𝐭𝐮𝐩 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: 𝐀𝐫𝐢𝐲𝐚 𝐁𝐢𝐨 - 𝐀 𝐔𝐧𝐢𝐪𝐮𝐞 𝐂𝐑𝐈𝐒𝐏𝐑-𝐁𝐚𝐬𝐞𝐝 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐨 𝐓𝐫𝐞𝐚𝐭 𝐇𝐚𝐞𝐦𝐨𝐠𝐥𝐨𝐛𝐢𝐧𝐨𝐩𝐚𝐭𝐡𝐢𝐞𝐬 Located in the ETH Innovation & Entrepreneurship Lab in Zürich (ETH Zürich, Switzerland), Ariya Bio's goal is to develop safe and effective gene-editing therapies for genetic diseases. Co-founded by Mandy Boontanrart, Jan Nelis and Jacob Corn, Ariya Bio's lead programmes currently focus on the beta-haemoglobinopathies, but the start-up has long-term plans to diversify to other disease areas. We recently spoke with Jan Nelis and Mandy Boontanrart to hear more about Ariya Bio and its unique approach to treating sickle cell disease. Read our interview here: https://lnkd.in/e97tkpYR #crisprmedicinenews #crisprmedicine #startup #sicklecelldisease #crispr #geneediting #genetherapy
News: Startup Spotlight: Ariya Bio - A Unique CRISPR-Based Approach to Treat Haemoglobinopathies - CRISPR Medicine
crisprmedicinenews.com